Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products derived from the human placenta, a non-controversial source, and not from embryonic stem cells. The placental cells are expanded in the Company’s proprietary PluriX™ 3D bioreactor and are termed PLX (PLacental eXpanded) cells. Pluristem’s PLX-I targets an annual $3 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT). The Company’s PLX-PAD targets an annual $4 billion market and is intended to improve the quality of life of millions of people suffering from Peripheral Artery Disease (PAD). Pluristem has previously announced its PLX cells can be therapeutically beneficial in the treatment of a variety of other indication, such as ischemic stroke and Parkinson’s Disease (PD).
Visit www.pluristem.com for more information